Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: a case series of 91 patients from Germany

Endres, Dominique; Luengen, Eva; Hasan, Alkomiet; Kluge, Michael; Froehlich, Sabrina; Lewerenz, Jan; Bschor, Tom; Haussleiter, Ida Sibylle; Juckel, Georg; Bergh, Florian Then; Ettrich, Barbara; Kertzscher, Lisa; Oviedo-Salcedo, Tatiana; Handreka, Robert; Lauer, Martin; Winter, Klaas; Zumdick, Norbert; Drews, Anna; Obrocki, Jost; Yalachkov, Yavor; Bubl, Anna; Podewils, Felix von; Schneider, Udo; Szabo, Kristina; Mattern, Margarete; Philipsen, Alexandra; Domschke, Katharina; Wandinger, Klaus-Peter; Neyazi, Alexandra; Stich, Oliver; Pruess, Harald; Leypoldt, Frank und Tebartz van Elst, Ludger (2022): Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: a case series of 91 patients from Germany. In: Molecular Psychiatry, Bd. 27, Nr. 3: S. 1479-1489

Abstract

Autoimmune encephalitis (AE) can rarely manifest as a predominantly psychiatric syndrome without overt neurological symptoms. This study's aim was to characterize psychiatric patients with AE;therefore, anonymized data on patients with suspected AE with predominantly or isolated psychiatric syndromes were retrospectively collected. Patients with readily detectable neurological symptoms suggestive of AE (e.g., epileptic seizures) were excluded. Patients were classified as probable psychiatric AE (pAE), if well-characterized neuronal IgG autoantibodies were detected or possible pAE (e.g., with detection of nonclassical neuronal autoantibodies or compatible cerebrospinal fluid (CSF) changes). Of the 91 patients included, 21 (23%) fulfilled our criteria for probable (autoantibody-defined) pAE and 70 (77%) those for possible pAE. Among patients with probable pAE, 90% had anti-NMDA receptor (NMDA-R) autoantibodies. Overall, most patients suffered from paranoid-hallucinatory syndromes (53%). Patients with probable pAE suffered more often from disorientation (p < 0.001) and impaired memory (p = 0.001) than patients with possible pAE. Immunotherapies were performed in 69% of all cases, mostly with high-dose corticosteroids. Altogether, 93% of the patients with probable pAE and 80% of patients with possible pAE reportedly benefited from immunotherapies (p = 0.251). In summary, this explorative, cross-sectional evaluation confirms that autoantibody-associated AE syndromes can predominantly manifest as psychiatric syndromes, especially in anti-NMDA-R encephalitis. However, in three out of four patients, diagnosis of possible pAE was based on nonspecific findings (e.g., slight CSF pleocytosis), and well-characterized neuronal autoantibodies were absent. As such, the spectrum of psychiatric syndromes potentially responding to immunotherapies seems not to be limited to currently known autoantibody-associated AE. Further trials are needed.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1359-4184
• Sprache: Englisch